Literature DB >> 29109297

IL-33/ST2 signaling boosts inflammation and pain.

Victor Fattori1, Sergio M Borghi1, Waldiceu A Verri2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29109297      PMCID： PMC5703330          DOI： 10.1073/pnas.1716120114

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


× No keyword cloud information.
  10 in total

1.  Spinal cord oligodendrocyte-derived alarmin IL-33 mediates neuropathic pain.

Authors:  Ana C Zarpelon; Francielle C Rodrigues; Alexandre H Lopes; Guilherme R Souza; Thacyana T Carvalho; Larissa G Pinto; Damo Xu; Sergio H Ferreira; Jose C Alves-Filho; Iain B McInnes; Bernhard Ryffel; Valérie F J Quesniaux; Flora Reverchon; Stéphane Mortaud; Arnaud Menuet; Foo Y Liew; Fernando Q Cunha; Thiago M Cunha; Waldiceu A Verri
Journal:  FASEB J       Date:  2015-08-26       Impact factor: 5.191

2.  IL-33 fine tunes mast cell degranulation and chemokine production at the single-cell level.

Authors:  Régis Joulia; Fatima-Ezzahra L'Faqihi; Salvatore Valitutti; Eric Espinosa
Journal:  J Allergy Clin Immunol       Date:  2016-11-19       Impact factor: 10.793

3.  IL-33/ST2 signaling excites sensory neurons and mediates itch response in a mouse model of poison ivy contact allergy.

Authors:  Boyi Liu; Yan Tai; Satyanarayana Achanta; Melanie M Kaelberer; Ana I Caceres; Xiaomei Shao; Jianqiao Fang; Sven-Eric Jordt
Journal:  Proc Natl Acad Sci U S A       Date:  2016-11-07       Impact factor: 11.205

4.  SP and IL-33 together markedly enhance TNF synthesis and secretion from human mast cells mediated by the interaction of their receptors.

Authors:  Alexandra Taracanova; Mihail Alevizos; Anna Karagkouni; Zuiy Weng; Errol Norwitz; Pio Conti; Susan E Leeman; Theoharis C Theoharides
Journal:  Proc Natl Acad Sci U S A       Date:  2017-05-01       Impact factor: 11.205

5.  Interleukin-33 mediates formalin-induced inflammatory pain in mice.

Authors:  P Han; J Zhao; S-B Liu; C-J Yang; Y-Q Wang; G-C Wu; D-M Xu; W-L Mi
Journal:  Neuroscience       Date:  2013-03-20       Impact factor: 3.590

6.  IL-33/ST2 signalling contributes to carrageenin-induced innate inflammation and inflammatory pain: role of cytokines, endothelin-1 and prostaglandin E2.

Authors:  A C Zarpelon; T M Cunha; J C Alves-Filho; L G Pinto; S H Ferreira; I B McInnes; D Xu; F Y Liew; F Q Cunha; W A Verri
Journal:  Br J Pharmacol       Date:  2013-05       Impact factor: 8.739

7.  IL-33 enhances lipopolysaccharide-induced inflammatory cytokine production from mouse macrophages by regulating lipopolysaccharide receptor complex.

Authors:  Quentin Espinassous; Elvira Garcia-de-Paco; Ignacio Garcia-Verdugo; Monique Synguelakis; Sonja von Aulock; Jean-Michel Sallenave; Andrew N J McKenzie; Jean Kanellopoulos
Journal:  J Immunol       Date:  2009-06-24       Impact factor: 5.422

8.  IL-33 mediates antigen-induced cutaneous and articular hypernociception in mice.

Authors:  Waldiceu A Verri; Ana T G Guerrero; Sandra Y Fukada; Daniel A Valerio; Thiago M Cunha; Damo Xu; Sérgio H Ferreira; Foo Y Liew; Fernando Q Cunha
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-04       Impact factor: 11.205

9.  IL-33 augments substance P-induced VEGF secretion from human mast cells and is increased in psoriatic skin.

Authors:  Theoharis C Theoharides; Bodi Zhang; Duraisamy Kempuraj; Michael Tagen; Magdalini Vasiadi; Asimenia Angelidou; Konstantinos-Dionysios Alysandratos; Dimitris Kalogeromitros; Shahrzad Asadi; Nikolaos Stavrianeas; Erika Peterson; Susan Leeman; Pio Conti
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-16       Impact factor: 11.205

10.  IL-33 exacerbates antigen-induced arthritis by activating mast cells.

Authors:  Damo Xu; Hui-Rong Jiang; Peter Kewin; Yubin Li; Rong Mu; Alasdair R Fraser; Nick Pitman; Mariola Kurowska-Stolarska; Andrew N J McKenzie; Iain B McInnes; Foo Y Liew
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-30       Impact factor: 11.205
  10 in total
  7 in total

1.  IL-33 enhances macrophage release of IL-1β and promotes pain and inflammation in gouty arthritis.

Authors:  Victor Fattori; Larissa Staurengo-Ferrari; Tiago H Zaninelli; Rubia Casagrande; Rene D Oliveira; Paulo Louzada-Junior; Thiago M Cunha; Jose C Alves-Filho; Mauro M Teixeira; Fernando Q Cunha; Flavio A Amaral; Waldiceu A Verri
Journal:  Inflamm Res       Date:  2020-09-04       Impact factor: 4.575

2.  Reply to Fattori et al.: Action of SP and IL-33 on mast cells.

Authors:  Theoharis C Theoharides; Alexandra Taracanova; Irene Tsilioni; Pio Conti; Susan E Leeman
Journal:  Proc Natl Acad Sci U S A       Date:  2017-11-06       Impact factor: 11.205

3.  Increased ratio of sST2/LVMI predicted cardiovascular mortality and heart failure rehospitalization in heart failure with reduced ejection fraction patients: a prospective cohort study.

Authors:  Fuhai Li; Mengying Xu; Mingqiang Fu; Xiaotong Cui; Zhexun Lian; Hui Xin; Jingmin Zhou; Junbo Ge
Journal:  BMC Cardiovasc Disord       Date:  2021-08-17       Impact factor: 2.298

Review 4.  IL33: Roles in Allergic Inflammation and Therapeutic Perspectives.

Authors:  Ben C L Chan; Christopher W K Lam; Lai-Shan Tam; Chun K Wong
Journal:  Front Immunol       Date:  2019-03-04       Impact factor: 7.561

Review 5.  Characteristics, mechanism, and management of pain in atopic dermatitis: A literature review.

Authors:  Jia-Xin Li; Rui-Jia Dong; Yue-Ping Zeng
Journal:  Clin Transl Allergy       Date:  2021-12       Impact factor: 5.871

6.  MicroRNA-547-5p-mediated interleukin-33/suppressor of tumorigenicity 2 signaling underlies the genesis and maintenance of neuropathic pain and is targeted by the therapy with bone marrow stromal cells.

Authors:  Ju Zhou; Ting Zhuang; Peng Ma; Lidong Shan; Xiao-Dong Sun; Shan Gong; Jin Tao; Xian-Min Yu; Xinghong Jiang
Journal:  Mol Pain       Date:  2020 Jan-Dec       Impact factor: 3.395

7.  IL-33/ST2 induces neutrophil-dependent reactive oxygen species production and mediates gout pain.

Authors:  Chengyu Yin; Boyu Liu; Yuanyuan Li; Xiaojie Li; Jie Wang; Ruixiang Chen; Yan Tai; Qiyang Shou; Ping Wang; Xiaomei Shao; Yi Liang; Hong Zhou; Wenli Mi; Jianqiao Fang; Boyi Liu
Journal:  Theranostics       Date:  2020-10-27       Impact factor: 11.556
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.